Minerva Neurosciences (NERV) Liabilities and Shareholders Equity (2013 - 2026)

Minerva Neurosciences' Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $94.0 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 186.68% year-over-year to $94.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $250.5 million (up 57.51% YoY) and the FY2025 annual result came in at $98.0 million, up 163.76% from the prior year.
• Liabilities and Shareholders Equity was $94.0 million for Q1 2026 at Minerva Neurosciences, down from $98.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $98.0 million in Q4 2025 and bottomed at $28.1 million in Q3 2025.
• A 5-year average of $55.8 million and a median of $55.1 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 38.75% — and 2026, when it soared 186.68%.
• Minerva Neurosciences' Liabilities and Shareholders Equity stood at $55.1 million in 2022, then advanced by 3.29% to $56.9 million in 2023, then slumped by 34.72% to $37.1 million in 2024, then soared by 163.76% to $98.0 million in 2025, then declined by 4.02% to $94.0 million in 2026.
• Business Quant data shows NERV's Liabilities and Shareholders Equity at $94.0 million in Q1 2026, $98.0 million in Q4 2025, and $28.1 million in Q3 2025.